1,3,5-Tri-O-Benzoyl-D-Ribofuranose

22224-41-5

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enter₹prise that is market-oriented and realizes industrial development through R&D© innovation and technology transformation.

key word:

Pharmaceutical industrial

Category:

Product Description

Integrity, innovation, cooperation, sharing, win-win

The company integrates multiple resources and strives to build a large health industry fin ance platform company integrating pharmaceutical, intelligent medical, bio pharmaceut≤ical R&D, industrial production and sales.

The chemical reactions involved in the existing products include Foucault reaction, nitration reαaction, sulfonation reaction, hydrogenation reaction, fluorinatio↓n reaction, chlorination reaction, bromination reaction, diazotization reaction, form™at reaction, etc.

Related products

Sitagliptin Phosphate Monohydrate

Sitagliptin phosphate is a dipeptidyl peptidase-4 (D★PP4) inhibitor developed by Merck. In October 2006, Sitagliptin phosphate Januvia was approved× by FDA as the first DPP4 inhibitor for the treatment of type ⅱ diabetes melli≤tus. The characteristics of this drug are that it can stimulate ins✘ulin secretion while reducing hunger without causing weightγ gain. Hypoglycemia and edema will not occur, and it is suitable for ∏diabetic patients with poor blood glucose control and frequent hypoglycemi×a.

Sumatriptan Succinate

Medication for migraine

Vildagliptin

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical Ωenterprise that is market-oriented and realizes industrial development through R&♠D innovation and technology transformation.

Ketoprofen

The non-steroidal anti-inflammatory drug ketoprofe®n is one of the most important products for the treatment of arthritis. It is well tolerated ¶and has a low incidence of side effects

Pranlukast

Pranlukast, developed by Ono, is one of the three major leukotriene receptor antagonists. In clini≥cal application, it has good therapeutic effect on atopic asthma and other typ₹es of bronchial asthma, and the market prospect is h←uge. In the major category of asthma drugs, leukotriene receptor antagonists have↑ the fastest growing market share.

Avanafil

Chenglian Pharmaceutical is an innovative high-tech pharmac☆eutical enterprise that is market-oriented and rea♦lizes industrial development through R&D innovation and ‍technology transformation.

Donepezil HCL

Treatment of mild to moderate Alzheimer's syndrome. It is ≠the second drug approved by FDA for Alzheimer's disease in the United States≥. Its treatment reaches the target dose and has low toxic and side✔ effects. It has been widely recognized by our medical community, and good tolerance is its bi®ggest advantage. In October 1999, Donepezil was lau☆nched in China under the trade name "Aricept", which is the main chemic×al drug against Alzheimer's disease. At present, CFDA has approved a number of dom estic enterprises to produce donepezil preparations, the m‍ain dosage forms are tablets, capsules, dispersive tablets, oral disintegrating tablets.Ω

Almotriptan

Migraine medication for adolescents

Apixaban

English name Apixaban Trade name ELIQUIS, tablet: Apixaban (Eliquis, Bristol∞-Myers Squibb/Pfizer), a direct oral factor Xa inhibitor, was approved for us¶e in the 27 EU member states. The world's first drug approve↔d to prevent venous thromboembolism (VTE) in adult patients undergoing elective hip o☆r knee replacement. From June 2019 to June 2020, the annual sales of apixaban products overseσas reached about $15.4 billion, with a year-on-year growth of nearly 32%, and the API ↔consumption reached about 23,960 kg, with a year-on-year growth of about 28%. Co♦mpared with its main competitor, Rivaroxaban, the drug's annua₹l overseas sales are about $4.5 billion higher.

Lenvatinib

Chenglian Pharmaceutical is an innovative high-tech pharmaceutical enterprise that i≠s market-oriented and realizes industrial development through R&D innovation and technology tran∞sformation.

Clofarabine

It is a nucleotide analogue developed by Bioenvision and manufactured by Genzyme. On December 29, 2≤004, it was approved by FDA for the treatment of refractory or relapsed acute lymphoblastic leukemiγa (ALL) in children.

Upadacitinib(Scientific research)

Chenglian Pharmaceutical is an innovative high-tech pharmaceuti​cal enterprise that is market-oriented and realizes industrial deveΩlopment through R&D innovation and technology transformation.

Product Consulting

Our staff will contact you within 24 hours (working days). If you need other services, E-mail: 2880705932@qq.com

Copyright © 2022 Anhui Union Pharmaceuticals Techno÷logy Co., Ltd.